CN103097358B - 药物组合物 - Google Patents
药物组合物 Download PDFInfo
- Publication number
- CN103097358B CN103097358B CN201180045222.XA CN201180045222A CN103097358B CN 103097358 B CN103097358 B CN 103097358B CN 201180045222 A CN201180045222 A CN 201180045222A CN 103097358 B CN103097358 B CN 103097358B
- Authority
- CN
- China
- Prior art keywords
- methyl
- hydrogen
- cancer
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[N+]/C(/Oc1cccc(C(F)(F)F)c1)=C(/C(C(F)I)=N)\C(NC(*)c(cc1)ccc1C(O)=O)=O Chemical compound C[N+]/C(/Oc1cccc(C(F)(F)F)c1)=C(/C(C(F)I)=N)\C(NC(*)c(cc1)ccc1C(O)=O)=O 0.000 description 4
- FQWAIOYNRZLUKT-UHFFFAOYSA-N C[n]1nc(C(F)(F)F)c(C(NC2(CC2)c(cc2)ccc2C(O)=O)=O)c1Oc(cc1Cl)ccc1Cl Chemical compound C[n]1nc(C(F)(F)F)c(C(NC2(CC2)c(cc2)ccc2C(O)=O)=O)c1Oc(cc1Cl)ccc1Cl FQWAIOYNRZLUKT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38478110P | 2010-09-21 | 2010-09-21 | |
| US61/384781 | 2010-09-21 | ||
| US61/384,781 | 2010-09-21 | ||
| PCT/US2011/051163 WO2012039972A1 (en) | 2010-09-21 | 2011-09-12 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103097358A CN103097358A (zh) | 2013-05-08 |
| CN103097358B true CN103097358B (zh) | 2015-04-08 |
Family
ID=44674894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180045222.XA Active CN103097358B (zh) | 2010-09-21 | 2011-09-12 | 药物组合物 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8686018B2 (enExample) |
| EP (2) | EP2619182B1 (enExample) |
| JP (1) | JP5956448B2 (enExample) |
| KR (1) | KR101911105B1 (enExample) |
| CN (1) | CN103097358B (enExample) |
| AU (1) | AU2011305872B2 (enExample) |
| BR (1) | BR112013002484B1 (enExample) |
| CA (1) | CA2806121C (enExample) |
| CL (1) | CL2013000675A1 (enExample) |
| CY (1) | CY1118680T1 (enExample) |
| DK (1) | DK2619182T3 (enExample) |
| ES (1) | ES2610185T3 (enExample) |
| HR (1) | HRP20170042T1 (enExample) |
| HU (1) | HUE031408T2 (enExample) |
| IL (1) | IL224288A (enExample) |
| LT (1) | LT2619182T (enExample) |
| ME (1) | ME02575B (enExample) |
| MX (1) | MX2013003162A (enExample) |
| MY (1) | MY162146A (enExample) |
| NZ (1) | NZ606629A (enExample) |
| PE (1) | PE20131343A1 (enExample) |
| PH (1) | PH12013500467A1 (enExample) |
| PL (1) | PL2619182T3 (enExample) |
| PT (1) | PT2619182T (enExample) |
| RS (1) | RS55566B1 (enExample) |
| RU (1) | RU2606510C2 (enExample) |
| SG (1) | SG188188A1 (enExample) |
| SI (1) | SI2619182T1 (enExample) |
| SM (2) | SMT201700008T1 (enExample) |
| UA (1) | UA113499C2 (enExample) |
| WO (1) | WO2012039972A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3296B1 (ar) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
| SG11201510121RA (en) | 2013-06-12 | 2016-01-28 | Kaken Pharma Co Ltd | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| CN110354266A (zh) * | 2014-05-23 | 2019-10-22 | 卫材 R&D 管理有限公司 | 用于治疗癌症的组合疗法 |
| UY36680A (es) | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas como inhibidores de quinasa |
| JP6689297B2 (ja) | 2015-07-23 | 2020-04-28 | 武田薬品工業株式会社 | 複素環化合物 |
| KR102684436B1 (ko) | 2015-10-16 | 2024-07-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Ep4 길항제 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| CN110621671A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物 |
| EP3625223B1 (en) | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| PE20191811A1 (es) | 2017-05-18 | 2019-12-26 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| PE20191814A1 (es) | 2017-05-18 | 2019-12-27 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| JP7065117B2 (ja) | 2017-05-18 | 2022-05-11 | イドーシア ファーマシューティカルズ リミテッド | Ｎ－置換インドール誘導体 |
| CN108929281B (zh) * | 2017-05-27 | 2021-12-24 | 华东师范大学 | 三氮唑类化合物及其合成方法和应用 |
| CN117643587A (zh) * | 2018-02-05 | 2024-03-05 | 深圳市原力生命科学有限公司 | 用于治疗癌症的杂二环羧酸 |
| EP4116291A4 (en) * | 2020-03-04 | 2024-03-06 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | SYNTHESIS OF A NEW EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION |
| CN114075140A (zh) * | 2020-08-18 | 2022-02-22 | 武汉人福创新药物研发中心有限公司 | 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途 |
| US20230390303A1 (en) | 2020-11-13 | 2023-12-07 | Ono Pharmaceutical Co., Ltd. | Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor |
| TWI877433B (zh) | 2020-11-30 | 2025-03-21 | 大陸商杭州阿諾生物醫藥科技有限公司 | 用於治療ｐｉｋ３ｃａ突變癌症的組合療法 |
| US20240409516A1 (en) * | 2021-01-28 | 2024-12-12 | Shenzhen Zhongge Biological Technology Co., Ltd. | Pyrazolamide derivative, preparation method therefor, and application thereof |
| CA3230557A1 (en) * | 2021-09-03 | 2023-03-09 | Xuejun Zhang | Ep4 antagonist compound as well as salt, polymorph, and use thereof |
| CN115364222A (zh) * | 2021-09-09 | 2022-11-22 | 首都医科大学附属北京地坛医院 | Ep4受体抑制剂治疗肝纤维化的应用 |
| CA3242277A1 (en) | 2021-12-23 | 2023-06-29 | Eisai R&D Management Co., Ltd. | Crystalline salt form of ep4 antagonist |
| US20250381143A1 (en) * | 2021-12-30 | 2025-12-18 | Adlai Nortye Biopharma Co., Ltd. | A solid pharmaceutical composition |
| WO2024027599A1 (zh) * | 2022-08-04 | 2024-02-08 | 杭州阿诺生物医药科技有限公司 | 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000020371A1 (en) * | 1998-10-07 | 2000-04-13 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| CN1950333A (zh) * | 2004-05-04 | 2007-04-18 | 辉瑞大药厂 | 取代的甲基芳基或杂芳基酰胺化合物 |
| CN101273013A (zh) * | 2005-09-27 | 2008-09-24 | 盐野义制药株式会社 | 具有pgd2受体拮抗活性的磺酰胺衍生物 |
| WO2009137338A1 (en) * | 2008-05-06 | 2009-11-12 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0421671A (ja) * | 1990-05-16 | 1992-01-24 | Mitsubishi Kasei Corp | ４―ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤 |
| IL104311A (en) * | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| US7393842B2 (en) | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| US7119108B1 (en) | 1999-10-18 | 2006-10-10 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| TW591020B (en) | 2001-06-20 | 2004-06-11 | Wyeth Corp | 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| WO2004037212A2 (en) | 2002-10-24 | 2004-05-06 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| FR2847160A1 (fr) | 2002-11-20 | 2004-05-21 | Oreal | Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| PL2298743T3 (pl) * | 2003-06-26 | 2013-02-28 | Novartis Ag | Inhibitory kinaz P38 na bazie 5-członowych heterocykli |
| WO2005021508A1 (en) * | 2003-09-03 | 2005-03-10 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| GT200500013A (es) | 2004-01-23 | 2005-08-10 | Amidas herbicidas | |
| BRPI0510598A (pt) * | 2004-05-04 | 2007-11-20 | Pfizer | compostos de amida de aril ou heteroaril substituìdos |
| US8952176B2 (en) | 2005-06-07 | 2015-02-10 | Shionogi & Co., Ltd. | Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity |
| US20090131470A1 (en) * | 2005-06-11 | 2009-05-21 | Vernalis R & D Limited | Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders |
| EP1953145B1 (en) | 2005-11-21 | 2015-11-04 | Shionogi & Co., Ltd. | Heterocyclic compound having inhibitory activity on 11-b-hydroxysteroid dehydrogenase type i |
| JP5218737B2 (ja) * | 2006-02-06 | 2013-06-26 | 大正製薬株式会社 | スフィンゴシン−１−リン酸結合阻害物質 |
| EP2035376B1 (en) | 2006-06-12 | 2014-08-27 | Merck Canada Inc. | Indoline amide derivatives as ep4 receptor ligands |
| CN101541778B (zh) | 2006-08-11 | 2014-10-08 | 默克加拿大有限公司 | 作为ep4受体配体的噻吩甲酰胺衍生物 |
| NZ577109A (en) | 2006-12-15 | 2011-12-22 | Glaxo Group Ltd | Benzamide derivatives as ep4 receptor agonists |
| US8158671B2 (en) | 2007-02-26 | 2012-04-17 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists |
| US7560936B1 (en) | 2007-04-24 | 2009-07-14 | Integrated Device Technology, Inc. | Method and apparatus for ground bounce and power supply bounce detection |
| JP5559678B2 (ja) | 2007-06-15 | 2014-07-23 | ビーエーエスエフ ソシエタス・ヨーロピア | ジフルオロメチル置換ピラゾール化合物の製造方法 |
| US20110028463A1 (en) | 2007-07-03 | 2011-02-03 | Astellas Pharma Inc. | Amide compounds |
| JP2010533736A (ja) | 2007-07-19 | 2010-10-28 | ハー・ルンドベック・アクチエゼルスカベット | ５員複素環アミドおよび関連化合物 |
| CL2008002241A1 (es) | 2007-07-31 | 2009-12-28 | Bayer Cropscience Sa | Compuestos derivados de (hetero)aril-metilen-n-cicloalquil carboxamida condensados de 6 elementos con n-sustituido; composicion funguicida que comprende uno de dichos compuestos; y metodo para el control hongos fitopatogenos de cultivos agricolas. |
| GB0721611D0 (en) | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
| SI2565191T1 (sl) | 2008-05-14 | 2014-12-31 | Astellas Pharma Inc. | Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije |
| WO2010012794A1 (en) | 2008-08-01 | 2010-02-04 | Bayer Cropscience Sa | Fungicide n-cycloalkyl-n-biphenylmethyl-carboxamide derivatives |
| CN102149384B (zh) * | 2008-08-14 | 2014-08-20 | 南京奥昭生物科技有限公司 | 作为ep4受体拮抗剂的杂环酰胺衍生物 |
| CN102224154A (zh) | 2008-09-25 | 2011-10-19 | 默克弗罗斯特加拿大有限公司 | 作为EP4受体拮抗剂的β-咔啉磺酰脲衍生物 |
-
2011
- 2011-09-12 HR HRP20170042TT patent/HRP20170042T1/hr unknown
- 2011-09-12 ME MEP-2017-3A patent/ME02575B/me unknown
- 2011-09-12 RU RU2013118209A patent/RU2606510C2/ru active
- 2011-09-12 DK DK11760631.9T patent/DK2619182T3/en active
- 2011-09-12 MY MYPI2013700146A patent/MY162146A/en unknown
- 2011-09-12 MX MX2013003162A patent/MX2013003162A/es active IP Right Grant
- 2011-09-12 PT PT117606319T patent/PT2619182T/pt unknown
- 2011-09-12 EP EP11760631.9A patent/EP2619182B1/en active Active
- 2011-09-12 SI SI201131067A patent/SI2619182T1/sl unknown
- 2011-09-12 CA CA2806121A patent/CA2806121C/en active Active
- 2011-09-12 AU AU2011305872A patent/AU2011305872B2/en active Active
- 2011-09-12 ES ES11760631.9T patent/ES2610185T3/es active Active
- 2011-09-12 CN CN201180045222.XA patent/CN103097358B/zh active Active
- 2011-09-12 BR BR112013002484-4A patent/BR112013002484B1/pt active IP Right Grant
- 2011-09-12 LT LTEP11760631.9T patent/LT2619182T/lt unknown
- 2011-09-12 SM SM20170008T patent/SMT201700008T1/it unknown
- 2011-09-12 HU HUE11760631A patent/HUE031408T2/en unknown
- 2011-09-12 PH PH1/2013/500467A patent/PH12013500467A1/en unknown
- 2011-09-12 PE PE2013000320A patent/PE20131343A1/es active IP Right Grant
- 2011-09-12 RS RS20170008A patent/RS55566B1/sr unknown
- 2011-09-12 KR KR1020137004494A patent/KR101911105B1/ko active Active
- 2011-09-12 WO PCT/US2011/051163 patent/WO2012039972A1/en not_active Ceased
- 2011-09-12 PL PL11760631T patent/PL2619182T3/pl unknown
- 2011-09-12 SG SG2013007174A patent/SG188188A1/en unknown
- 2011-09-12 NZ NZ60662911A patent/NZ606629A/en unknown
- 2011-09-12 EP EP16161460.7A patent/EP3061751A1/en not_active Withdrawn
- 2011-09-12 JP JP2013530177A patent/JP5956448B2/ja active Active
- 2011-09-12 UA UAA201304961A patent/UA113499C2/uk unknown
-
2013
- 2013-01-17 IL IL224288A patent/IL224288A/en active IP Right Grant
- 2013-03-12 CL CL2013000675A patent/CL2013000675A1/es unknown
- 2013-03-12 US US13/795,768 patent/US8686018B2/en active Active
-
2014
- 2014-02-05 US US14/173,170 patent/US9000024B2/en active Active
-
2017
- 2017-01-09 SM SM201700008T patent/SMT201700008B/it unknown
- 2017-01-19 CY CY20171100079T patent/CY1118680T1/el unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000020371A1 (en) * | 1998-10-07 | 2000-04-13 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| CN1950333A (zh) * | 2004-05-04 | 2007-04-18 | 辉瑞大药厂 | 取代的甲基芳基或杂芳基酰胺化合物 |
| CN101273013A (zh) * | 2005-09-27 | 2008-09-24 | 盐野义制药株式会社 | 具有pgd2受体拮抗活性的磺酰胺衍生物 |
| WO2009137338A1 (en) * | 2008-05-06 | 2009-11-12 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103097358B (zh) | 药物组合物 | |
| RU2627268C2 (ru) | Аза-арил-1Н-пиразол-1-ил-сульфонамиды | |
| CN102149384B (zh) | 作为ep4受体拮抗剂的杂环酰胺衍生物 | |
| ES2526981T3 (es) | N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje | |
| CN106536520B (zh) | 芳基受体调制剂及其制备和使用方法 | |
| WO2012103071A2 (en) | Compounds and compositions | |
| JP6139690B2 (ja) | ブルートンチロシンキナーゼの阻害剤 | |
| JP4698681B2 (ja) | アミノピリミジン類の化合物及びその塩の調製方法と薬物の用途 | |
| KR20180119582A (ko) | 라이실 옥시다제의 인돌 및 아자인돌 할로알릴아민 유도체 억제제 및 이의 용도 | |
| TW200808805A (en) | Tetrahydropteridines useful as inhibitors of protein kinases | |
| CN101636385B (zh) | 作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物 | |
| CN107635404A (zh) | 用于治疗疾病的mct4抑制剂 | |
| CN107735401A (zh) | 取代二氢吡咯并吡唑衍生物 | |
| JP2022549601A (ja) | ヘテロアリール血漿カリクレインインヒビター | |
| JP2015531395A (ja) | ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤 | |
| WO2018157801A1 (zh) | 氰基取代的稠合双环衍生物及其制备方法和用途 | |
| JP2009538312A (ja) | イミダゾアゼピノン化合物 | |
| WO2020029908A1 (zh) | 螺桥环化合物、其药物组合物及其用途 | |
| JP4275947B2 (ja) | 三環式化合物およびその使用 | |
| HK1181765B (en) | Pharmaceutical composition | |
| HK1181765A (en) | Pharmaceutical composition | |
| AU2024320585A1 (en) | Novel compound, and pharmaceutical composition for prevention or treatment of cancer or tumors comprising same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130508 Assignee: Hangzhou Arnold Biomedical Technology Co.,Ltd. Assignor: Eisai Co.,Ltd. Contract record no.: X2021990000795 Denomination of invention: Pharmaceutical composition Granted publication date: 20150408 License type: Exclusive License Record date: 20211217 |
|
| EE01 | Entry into force of recordation of patent licensing contract |